Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray CrystallographyPeter Orth, Alex G. Therien, Fred Racine et al.|Journal of Biological Chemistry|2014Cited by 138
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosaKatherine Young, Mary Motyl, Ronald E. Painter et al.|BMC Microbiology|2019Cited by 126
Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope ModelingLorraine D. Hernandez, Alex G. Therien, Fred Racine et al.|Antimicrobial Agents and Chemotherapy|2014Cited by 54
Elucidation of DnaE as the Antibacterial Target of the Natural Product, NargenicinRonald E. Painter, Katherine Young, Gregory C. Adam et al.|Chemistry & Biology|2015Cited by 40
Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumabPeter Orth, Alex G. Therien, Le Xiao et al.|Unknown|2013Cited by 0